Browsing: PICO

Semaglutide

Semaglutide and Obesity-Related Heart Failure

By FWADecember 27, 20240

Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…

PICO

Tirzepatide Phase 1 Trial

By FWADecember 27, 20240

Summary: In adults with long-standing T2D inadequately controlled on current therapy, subcutaneous tirzepatide (dual GIP/GLP-1 agonist) in Phase 1 trial…

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

CONTACT INFO

Privacy Policy
Disclaimer

Browsing: PICO

Semaglutide and Obesity-Related Heart Failure

Tirzepatide Phase 1 Trial

Once-Weekly Semaglutide Shows Promise in Improving Glycaemic Control and Weight Loss for Type 2 Diabetes Patients, Study Finds

Study Finds Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes Patients, but Raises Retinopathy Concerns

Study Shows Once-Weekly Semaglutide Effectively Lowers Blood Sugar and Aids Weight Loss in Type 2 Diabetes Patients

Once-Weekly Semaglutide Outperforms Daily Sitagliptin in Blood Sugar and Weight Control for Type 2 Diabetes Patients

Subscribe now

CATEGORIES

CONTACT INFO